CLAIMS

1. A formulation comprising an effective amount of migalastat or salt thereof for use in reducing left ventricular mass index (LVMi) in an enzyme replacement therapy (ERT)-experienced patient having Fabry disease, wherein the effective amount is about 123 mg free base equivalent (FBE) and the formulation is administered to the patient every other day.

2. The formulation for use of claim 1, wherein the patient has left ventricular hypertrophy (LVH) prior to initiating administration of the formulation.

3. The formulation for use of claim 1 or 2, wherein the administration of the formulation enhances α-galactosidase A activity.

4. The formulation for use of any one of claims 1-3, wherein the effective amount of migalastat or salt thereof is about 123 mg of migalastat free base.

5. The formulation for use of any one of claims 1-3, wherein the effective amount of migalastat or salt thereof is about 150 mg of migalastat hydrochloride.

6. The formulation for use of any one of claims 1-5, wherein the formulation comprises an oral dosage form.

7. The formulation for use of claim 6, wherein the oral dosage form comprises a tablet, a capsule or a solution.

8. The formulation for use of any one of claims 1-7, wherein the formulation is administered for at least 18 months.

9. The formulation for use of any one of claims 1-8, wherein the formulation is administered for at least 30 months.

10. The formulation for use of any one of claims 1-9, wherein the administration of the formulation provides an average decrease of LVMi in a group of ERT-experienced patients of at least about 5 g/m^2 after 18 months of administration of the formulation.

11. The formulation for use of any one of claims 1-10, wherein the administration of the formulation provides an average decrease of LVMi in a group of ERT-experienced patients of about 6.6 g/m^2 after 18 months of administration of the formulation.

12. The formulation for use of any one of claims 1-11, wherein the administration of the formulation provides an average decrease of LVMi in a group of ERT-experienced patients of at least about 2 g/m^2 after 30 months of administration of the formulation.

13. The formulation for use of any one of claims 1-12, wherein the administration of the formulation provides an average decrease of LVMi in a group of ERT-experienced patients of about 3.8 g/m^2 after 30 months of administration of the formulation.

14. The formulation for use of any one of claims 1-13, wherein the administration of the formulation provides an average decrease of LVMi in a group of ERT-experienced patients with LVH of at least about 5 g/m^2 after 30 months of administration of the formulation.

15. The formulation for use of any one of claims 1-14, wherein the administration of the formulation provides an average decrease of LVMi in a group of ERT-experienced patients with LVH of about 9 g/m^2 after 30 months of administration of the formulation.

16. The formulation for use of any one of claims 1-15, wherein the administration of the formulation normalizes LVMi in a patient with LVH prior to initiating administration of the formulation.